SRI 2023 Annual Scientific Meeting, March 21-25

Brisbane, Australia

Important Dates

  • October 14, 2022: Abstract Submission Deadline
  • January 30, 2023: Advance Registration Deadline
  • February 17, 2023: Housing Deadline
  • February 27, 2023: Online Registration Closes
  • March 21- 25, 2023: 70th Annual Meeting

Carole R. Mendelson, PhD, 2023 SRI President

Mana Parast, MD, PhD, 2023 SRI Program Director

President’s Message

June 1, 2022

Dear SRI Colleagues,

The summer months are finally upon us in North America! Summer at SRI includes committee meetings and lots of planning for the upcoming Annual Meeting! This Society depends upon the loyalty, volunteerism and commitment of its members. This is so apparent in the hard work that is going into the planning of what looks like a spectacular meeting in Brisbane next March by Drs. Mana Parast, Program Director, Bo Rueda, Program Committee Chair, Program Committee members and symposia leaders. The Program Committee met last week to discuss the mini-symposia proposals submitted for the 2023 Annual Meeting. The basic, clinical and translational science that will be presented is state-of-the-art and so very exciting. Watch for more details on the 2023 Annual Meeting website – new information will be available soon. Also – start planning for your travel to Brisbane, an excellent destination to visit and for extended travel to other great Australian cities and the Great Barrier Reef.

I also would like to let you know that we have confirmed two of the President’s Distinguished Lecturers who will be joining us in Brisbane. Sing Sing Way, MD, PhD, is the Pauline and Lawson Reed Chair of the Division of Infectious Diseases and a Professor of Pediatrics at Cincinnati Children’s Hospital and the University of Cincinnati College of Medicine. Dr. Way is expert in the immunological basis for recurrent pregnancy loss and the roles of regulatory T cells in maintaining immune tolerance to the fetus during pregnancy. The SRI also will be hosting Jennifer K. Richer, PhD, from the University of Colorado Anschutz Medical Campus, where she is a Professor of Pathology and Co-Leader of the Tumor Host Interactions Program at the University of Colorado Cancer Center. Dr. Richer is an expert on the roles of estrogen receptors (ER), androgen receptors (AR) and microRNAs in breast cancer pathogenesis and harnessing of this knowledge to improve breast cancer responsiveness to endocrine therapy. Her research on the AR in breast cancer has led to two investigator initiated clinical trials.

Best wishes for a wonderful and safe summer.car

Carole Mendelson, PhD, SRI President, 2022-2023

SRI Annual Meeting 2023